Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2018

View Archived Issues

Total surveillance leads to cell division atlas

Mutations in IRF2BPL causes neurodegeneration in humans and flies

ASD diagnosis branches out

Cancer immunotherapy could get metabolic leg up

FDA approves Ajovy for preventive treatment of migraine

AstraZeneca adopts Horizon Discovery's Edit-R crRNA libraries for genomics discovery platform

Efgartigimod phase II data in ITP support progression to phase III development

Azitra, The Jackson Laboratory awarded grant to identify compounds for treatment of skin infections

Glenmark to use Mitra's CANscript platform in support of immuno-oncology pipeline

CymaBay opens enrollment in phase III study of seladelpar for primary biliary cholangitis

Palobiofarma enrolling patients in phase I study of PBF-1129 for NSCLC

Gilead Sciences and Precision BioSciences collaborate to develop therapies against HBV

MaxCyte studies MCY-M11 in phase I for advanced ovarian cancer and peritoneal mesothelioma

Zhejiang Beta Pharma patents fibroblast growth factor receptor inhibitors

AbbVie presents novel optimized GABA-B PAMs with efficacy in animal models of seizure

DGMIF presents DN-200434 for ATC radioiodine therapy improvement

Strategic alliance between Bayer and Evotec results in the discovery of BAY-2395840

Targeting alpha-4 integrin alleviates allergic conjunctivitis in animal models

First phase I data presented for inhaled pirfenidone

Bristol-Myers Squibb initiates two phase III trials of BMS-986165 in plaque psoriasis

Integrin alphaVbeta6 PET tracer shows promise for assessment of interstitial lung disease

Phase II data presented for CFTR potentiator QBW-251

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...